Publications by authors named "R C Inhorn"
Article Synopsis
- - Genomic tumor testing (GTT) aims to identify specific tumor variants that can be treated with targeted drugs, but access is often limited for rural patients in community oncology settings.
- - In a study involving 1,603 adult cancer patients in Maine, 1,258 had actionable variants identified, leading to 240 genome-matched treatments, with a notable survival benefit for those treated (31% less likely to die within one year).
- - The results indicate that while GTT can provide effective treatment options in rural areas, there is still a need to increase the availability of clinical trials and improve the infrastructure supporting these tests.
Background: Seminal trials have demonstrated improved survival in pancreatic adenocarcinoma with novel multiagent chemotherapy regimens. To understand the clinical ramifications of this paradigm shift, we reviewed our institutional experience.
Methods: This retrospective cohort study utilized a prospective database at a single institution to study all patients diagnosed with and treated for pancreatic adenocarcinoma between 2000 and 2020.
Article Synopsis
- - The Maine Cancer Genomics Initiative (MCGI) aimed to improve genomic tumor testing access for cancer patients in rural Maine through genomic tumor boards, clinician education, and free testing services from 2016 to 2020.
- - A hub-and-spoke model was adopted for the initiative, involving a centralized genomic tumor board program, an online education module, and comprehensive testing that engaged all 19 oncology practices in Maine, with participation from 79 oncologists.
- - The initiative successfully enrolled 1610 patients, held 196 genomic tumor boards with 47 clinicians, and achieved significant improvements in clinician participation and patient enrollment in a rural setting, enhancing precision oncology accessibility.
Purpose: Ixabepilone is a microtubule stabilizer with activity in taxane-refractory metastatic breast cancer and low susceptibility to taxane-resistance mechanisms including multidrug-resistant phenotypes and high β-III tubulin expression. Since these resistance mechanisms are common in triple-negative breast cancer (TNBC), ixabepilone may have particular advantages in this patient population. This study evaluated the substitution of ixabepilone for paclitaxel following doxorubicin/cyclophosphamide (AC) in the adjuvant treatment of early-stage TNBC.
View Article and Find Full Text PDFBackground: The purposes of the present phase I/II trial were (1) to define tolerable doses of ixabepilone and sorafenib when used in combination and (2) to evaluate the efficacy and toxicity of this combination in the treatment of patients with human epidermal growth factor receptor-negative metastatic breast cancer (MBC).
Patients And Methods: The eligible patients had human epidermal growth factor receptor-negative MBC and had not received previous chemotherapy in the metastatic setting. All patients received ixabepilone intravenously on day 1 of each 21-day treatment cycle; sorafenib was administered orally twice daily.